Several clinical trials, based on the use of autologous or allogeneic NK cells, are being performed in field of multiple myeloma and some of them combine NK-cells with anti-CD38 mAbs (ClinicalTrials.gov Identifier: NCT04558931). This evidence concerns the gene CD38 and plasma cell myeloma.